New drug cocktail shows promise in taming early-stage bone marrow cancer

NCT ID NCT01816971

First seen Apr 25, 2026 · Last updated May 10, 2026 · Updated 4 times

Summary

This study tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) given before and after a stem cell transplant in 76 people newly diagnosed with multiple myeloma, a type of blood cancer. The goal was to see how well the treatment could control the disease. While the approach aims to reduce cancer cells, patients may need ongoing therapy to manage the condition, so it is not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE I MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber

    Boston, Massachusetts, 02215, United States

  • Princess Margaret

    Toronto, Ontario, M5T 2M9, Canada

  • Sarah Cannon Cancer Center

    Nashville, Tennessee, 37203, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637-1470, United States

  • Washington University in St Louis

    St Louis, Missouri, 63130, United States

Conditions

Explore the condition pages connected to this study.